Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001228388 | SCV001400785 | pathogenic | Neurofibromatosis, type 1 | 2021-04-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Leu1390 amino acid residue in NF1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 19845691). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NF1 protein function. This variant has been observed in individual(s) with neurofibromatosis type 1 (PMID: 16835897). This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 1390 of the NF1 protein (p.Leu1390Pro). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and proline. |